EGFR and neoplasm: Cetuximab and similar human epidermal growth factor receptor (HER) family targeting antibodies are thought to interact with tumor cells through two mechanisms: direct inhibition of ligand binding and thus downstream signaling, and induction of antibody-dependent cell-mediated cytotoxicity (ADCC), whereby natural killer cells and macrophages are recruited to the tumor cells and induce apoptosis 32,33.